China: Cell and Gene Therapy mRNA Drugs China Launches its Largest Commercial GMP Plasmid Manufacturing Plant
Genscript Probio has inaugurated its mega facility which is claimed to be China’s largest commercial GMP plasmid manufacturing plant. The plant will enable the firm to offer customers across the globe a one-stop service for plasmids. The move is expected to speed up the innovation and development of high-quality cell and gene therapy mRNA drugs.
Nanjing/China – Genscript Probio recently announced the inauguration of China's largest commercial GMP plasmid manufacturing facility during a ceremony at the site in Zhenjiang, Jiangsu Province. The 6,400-square-meter manufacturing plant enables the firm to offer global customers a one-stop service for plasmids - from preclinical study (IIT), to investigational new drug (IND) filing, to clinical trial and commercial manufacturing - to accelerate the innovation and development of high-quality cell and gene therapy mRNA drugs.
As Genscript Probio's second GMP plasmid manufacturing facility, the plant more than doubles the company's production capacity and strengthens its position as a leading CDMO. It enables the company to offer services including off-the-shelf LentiHelp plasmids, Pro grade plasmids for preclinical development, plasmids CMC study for IND filing, clinical GMP plasmids for early clinical trials, and cGMP plasmids for late-phase and commercialization.
The facility also expands the company’s operations, which already included the largest commercial GMP plasmid manufacturing facility in China.